UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 331

Sortiert nach

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

PLoS neglected tropical diseases, 2017-05, Vol.11 (5), p.e0005527-e0005527

2017

Volltextzugriff (PDF)

Global Burden of Human Papillomavirus and Related Diseases

Vaccine, 2012-11, Vol.30, p.F12-F23

2012

Volltextzugriff (PDF)

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Vaccine, 2006-08, Vol.24, p.S35-S41

2006

Volltextzugriff (PDF)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice

Vaccine, 2016-07, Vol.34 (35), p.4123-4131

2016

Volltextzugriff (PDF)

Hepatitis B Vaccination Induces Mucosal Antibody Responses in the Female Genital Tract, Indicating Potential Mechanisms of Protection Against Infection

Sexually transmitted diseases, 2019-05, Vol.46 (5), p.e53-e56

2019

Volltextzugriff (PDF)

Characterization of a new Leishmania major strain for use in a controlled human infection model

Nature communications, 2021-01, Vol.12 (1), p.215-215, Article 215

2021

Volltextzugriff (PDF)

Neurocognitive function in HIV infected patients on antiretroviral therapy

PloS one, 2013-04, Vol.8 (4), p.e61949-e61949

2013

Volltextzugriff (PDF)

Overcoming roadblocks in the development of vaccines for leishmaniasis

Expert review of vaccines, 2021-11, Vol.20 (11), p.1419-1430

2021

Volltextzugriff (PDF)

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

The Lancet (British edition), 2010-10, Vol.376 (9749), p.1329-1337

2010

Volltextzugriff (PDF)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

Molecular therapy, 2021-07, Vol.29 (7), p.2366-2377

2021

Volltextzugriff (PDF)

Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis

Nature medicine, 2024-08

2024

Volltextzugriff (PDF)

Microbicides and HIV prevention: lessons from the past, looking to the future

Current opinion in infectious diseases, 2010-02, Vol.23 (1), p.57-63

2010

Volltextzugriff (PDF)

Unresolved issues in the management of human papillomavirus-associated mucosal high-grade pre-cancers

Tumour virus research, 2023-06, Vol.15, p.200250-200250, Article 200250

Lacey, Charles JN

2023

Volltextzugriff (PDF)

Vaccines against leishmaniasis: using controlled human infection models to accelerate development

Expert review of vaccines, 2021-11, Vol.20 (11), p.1407-1418

2021

Volltextzugriff (PDF)

Therapeutic Vaccination With Recombinant Adenovirus Reduces Splenic Parasite Burden in Experimental Visceral Leishmaniasis

The Journal of infectious diseases, 2012-03, Vol.205 (5), p.853-863

2012

Volltextzugriff (PDF)

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study

PloS one, 2016-05, Vol.11 (5), p.e0152038-e0152038

2016

Volltextzugriff (PDF)

MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide

PloS one, 2014-12, Vol.9 (12), p.e116153-e116153

2014

Volltextzugriff (PDF)

Therapy of Human Papillomavirus-Related Disease

Vaccine, 2012-11, Vol.30 (5), p.F71-F82

2012

Volltextzugriff (PDF)

Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination

The Journal of infectious diseases, 2005-12, Vol.192 (12), p.2099-2107

2005

Volltextzugriff (PDF)

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

The Lancet global health, 2022-10, Vol.10 (10), p.e1485-e1493

2022

Volltextzugriff (PDF)

Cervico-vaginal immunoglobulin G levels increase post-ovulation independently of neutrophils

PloS one, 2014-12, Vol.9 (12), p.e114824-e114824

2014

Volltextzugriff (PDF)

Therapy for genital human papillomavirus-related disease

Journal of clinical virology, 2005-03, Vol.32 (S), p.82-90

Lacey, Charles J.N.

2005

Volltextzugriff (PDF)

A clinical study to optimise a sand fly biting protocol for use in a controlled human infection model of cutaneous leishmaniasis (the FLYBITE study)

Wellcome open research, 2021, Vol.6, p.168

2021

Volltextzugriff (PDF)

Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT

Health technology assessment (Winchester, England), 2020-09, Vol.24 (47), p.1-86

2020

Volltextzugriff (PDF)

1 – 25 von 331

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(302)
Mit Volltextzugriff
(285)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(330)
Japanisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

Global Burden of Human Papillomavirus and Related Diseases

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice

Hepatitis B Vaccination Induces Mucosal Antibody Responses in the Female Genital Tract, Indicating Potential Mechanisms of Protection Against Infection

Characterization of a new Leishmania major strain for use in a controlled human infection model

Neurocognitive function in HIV infected patients on antiretroviral therapy

Overcoming roadblocks in the development of vaccines for leishmaniasis

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis

Microbicides and HIV prevention: lessons from the past, looking to the future

Unresolved issues in the management of human papillomavirus-associated mucosal high-grade pre-cancers

Vaccines against leishmaniasis: using controlled human infection models to accelerate development

Therapeutic Vaccination With Recombinant Adenovirus Reduces Splenic Parasite Burden in Experimental Visceral Leishmaniasis

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study

MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide

Therapy of Human Papillomavirus-Related Disease

Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic Vaccination

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

Cervico-vaginal immunoglobulin G levels increase post-ovulation independently of neutrophils

Therapy for genital human papillomavirus-related disease

A clinical study to optimise a sand fly biting protocol for use in a controlled human infection model of cutaneous leishmaniasis (the FLYBITE study)

Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT

Suchergebnisse filtern